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We describe an unusual case of hypoglycemic syndrome in a 69-year old woman with a proinsulin-only secreting pancreatic
endocrine adenoma. The clinical history was highly suggestive of an organic hypoglycemia, with normal or relatively low insulin
concentrations and elevated proinsulin levels. Magnetic resonance and computed tomography of the abdomen showed a 1cm
pancreatic nodule and multiple accessory spleens. The diagnosis was conﬁrmed by selective angiography, showing location and
vascularization of the nodule, despite no response to intra-arterial calcium. After resection, the hypoglycemic syndrome resolved.
The surgical specimen was comprised of a neuroendocrine adenomatous tissue with high proinsulin immunoreactivity. Study
of this unusual case of proinsulinoma underlines (i) the need to assay proinsulin in patients with hypoglycemia and normal
immunoreactive insulin, (ii) the diﬀerential diagnosis in the presence of accessory spleens, (iii) the unresponsiveness to intra-
arterial calcium stimulation, and (iv) the extensive evaluation needed to reach a ﬁnal diagnosis.
1.Introduction
The most common cause of organic fasting hypoglycemia in
the adult is the presence of an insulin-producing pancreatic
adenoma. The clinical diagnosis is relatively simple, but
tumorlocalizationisoftenchallenging.Insomecases,insulin
concentrations are low despite a clinical history suggestive of
pancreatic adenoma. In these cases, a proinsulinoma should
be suspected. However, the rarity of this condition requires
an extensive workup before reaching a ﬁnal diagnosis.
2. Case Presentation
2.1. History. On August 2009, a 69-year old woman was
admitted to the Division of Metabolic Diseases for recur-
rent episodes of hypoglycemia. About one month earlier,
she began reporting symptoms of hypoglycemia (blurred
vision, weakness, dizziness, sweating, mild tremor, hunger,
paresthesia, and confusion), occurring in fasting conditions
early in the morning and >4 hours after meals. On several
occasions, during these episodes capillary glucose was found
to be between 2.2 and 2.8mmol/L (about 40–50mg/dL),
but she never lost consciousness. The patient had to snack
several times a day to counter symptoms, and her body
weight had increased by about 3kg in 4 weeks. Her medical
history included hypertension treated with an ACE inhibitor,
remote Basedow’s disease, and hypercholesterolemia on
atorvastatin.Shedeniedtheuseofinsulinororalantidiabetic
medications. On admission, her vital signs were normal
(blood pressure 140/80mm Hg, heart rate 72bpm), and
physical examination was unremarkable.
2.2. Diﬀerential Diagnosis. During the hospital stay, the
patient was subjected to serial measurements of glucose,
insulin and c-peptide serum concentrations before and after
meals. Glucose levels were low before meals and within
the normal range after meals; insulin and c-peptide con-
centrations physiologically increased after meals (Table 1).2 Case Reports in Medicine
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Figure 1: Imaging studies and intraoperative appearance. (a) A contrast-enhanced computed tomography slice of the upper abdomen,
showing a mildly hyperintense nodule, about 1cm in diameter, located between the body and the tail of the pancreas (red arrow). (b) A
gadolinium-enhanced magnetic resonance slice of the upper abdomen, showing a mildly hyperintense nodule, about 1cm in diameter
between the body and the tail of the pancreas (red arrow), in the same location as identiﬁed by CT. (c) A digital subtraction angiography
with the catheter positioned in the proximal splenic artery, showing nodular vascularization from the arteria pancreatica magna (red arrow).
(d)IsolationandenucleationoftheadenomausingtheCUGAExcelsystem.(e)Macroscopicappearanceoftheadenomasoonafterresection
(scale bar in cm).
Table 1: Daytime glucose, insulin and c-peptide variations during
hospitalstay.Insulinandc-peptideweremeasuredusingautomated
immunoassays from American Systems DPS (Diagnostic Products
Corporation) optimized on a Siemens Immulite 2000 c  platform.
Glicemia
mmol/L
(mg/dL)
Insulina
pmol/L
(mU/L)
c-peptide
pmol/L (µg/L)
Before breakfast 1.9 (34) 39 (5.4) 0.60 (1.8)
After breakfast 5.2 (94) 79 (11.0) 1.12 (3.4)
Before lunch 3.0 (54) 62 (8.6) 0.82 (2.5)
After lunch 7.7 (139) 113 (15.7) 1.56 (4.7)
Before dinner 3.3 (59) 80 (11.1) 1.23 (3.7)
After dinner 4.9 (88) 54 (7.5) 0.99 (3.0)
Fasting proinsulin concentration (measured by the EIA kit,
DRG Instruments GmBH, Germany) was markedly elevated
(7.2pmol/L (64pg/mL); normal 1.1pmol/L (10pg/L)). A
75g oral glucose tolerance test revealed normal glucose
tolerance (2 hour plasma glucose 7.4mmol/L (134mg/dL))
with no hypoglycemia up to 300 minutes, making reac-
tive hypoglycemia less likely. Then, a 72-hour prolonged
supervised fast was initiated: the test was interrupted
after 23 hours with a typical Whipple triad (plasma glu-
cose 1.9mmol/L (34mg/dL) and hypoglycemic symptoms
resolved after ingestion of sugar and recovery of normal
glucose levels); concomitantly, plasma insulin and c-peptide
concentrations were 9pmol/L (1.2mU/L) and 0.26nmol/L
(0.8µg/L), respectively, thus ruling out typical insulin-
producing adenoma. These ﬁndings were suggestive of
an organic hypoglycemic syndrome. Although insulin and
c-peptide were not always completely suppressed during
hypoglycemicepisodes,thelowplasmainsulinconcentration
and the elevated proinsulin levels indicated a proinsulinoma
or a predominantly proinsulin-secreting adenoma. Then,
the patient underwent a magnetic resonance scan of the
abdomen, which revealed a rounded, solid nodule of about
10mm in diameter located between the body and the tail
of the pancreas. Given that MIR sometimes failed to exactly
locate the pancreatic adenomas, this ﬁnding was conﬁrmed
by a CT scan, which also revealed the presence of multiple
accessory spleens located within the spleen ilum and near
the pancreatic tail (Figures 1(a) and 1(b)). An endoscopic
ultrasound examination, with the US probe positioned in
the large gastric curve, showed multiple accessory spleens
near the tail of the pancreas that were mobile with changing
decubitus, but was unable to locate the pancreatic nodule.
During diﬀerential workup, the patient was advised to have
multiple small meals and avoid sugars. Diazoxide was not
administered because the patient could conduct a near-
normal life by following dietary advices.
In light of instrumental ﬁndings, to rule out misdiag-
nosis of an accessory spleen as a pancreatic tail nodule, a
selective angiography was performed with venous sampling
[1]. Through femoral arteriotomy, a digital subtraction
angiography was ﬁrst performed with the catheter placed
at the origin of the splenic artery. Then, a venous catheter
was placed in the left suprahepatic vein, and stimuli withCase Reports in Medicine 3
Table 2: Results of the venous sampling during selective angiography (Imamura test). Normal range for insulin concentration was 43–
210pmol/L (6.0–29.1mU/L) and for proinsulin concentration was <1.1pmol/L (10pg/mL).
Time after Ca2+-gluconate bolus
Artery Analyte 0 30 60 120
Splenic
Insulin, pmol/L (mU/L) 55 (7.6) 55 (7.6) 62 (8.6) 67 (9.3)
Proinsulin, pmol/L (pg/mL) 20 (185) 20 (176) 14 (131) 20 (176)
Glucose, mmol/L (mg/dL) 3.0 (54) 3.1 (55) 2.8 (51) 2.9 (53)
Distal splenic
Insulin 43 (6.0) 32 (4.4) 46 (6.4) 65 (9.0)
Proinsulin 18 (155) 16 (145) 15 (132) 27 (234)
Glucose 3.0 (54) 2.4 (43) 2.7 (49) 3.3 (60)
Superior mesenteric
Insulin 32 (4.5) <14 (2.0) 60 (8.3) 43 (6.0)
Proinsulin 19 (166) 22 (192) 22 (196) 24 (212)
Glucose 2.6 (47) 2.1 (37) 3.1 (55) 3.3 (60)
Gastroduodenal
Insulin 53 (7.4) 37 (5.1) 38 (5.3) 42 (5.8)
Proinsulin 19 (166) 20 (179) 18 (163) 18 (155)
Glucose 2.6 (47) 2.8 (50) 3.2 (58) 3.1 (56)
0.05mmol/Kg calcium gluconate were performed through
the arterial catheter placed in the superior mesenteric artery,
gastroduodenal artery proximal, and distal splenic arteries.
Blood samples were drawn before and 30, 60, 120 seconds
after the infusion of calcium gluconate. Digital angiography
showed the presence of a 10-mm vascularized nodule in
the pancreatic tail, served by the arteria pancreatica magna.
Radioimmunological insulin and c-peptide determinations
showed physiological values with no response to any of the
calcium gluconate stimuli. Proinsulin concentrations were
markedlyelevatedwithnoresponsetolocalstimuli(Table2).
2.3. Treatment. Based on clinical, biochemical, and imaging
studies, the patient was referred to a surgical division (F.M.
andM.P.)withlong-standingexperienceinthediagnosisand
treatmentofendocrine pancreatictumors[2]. Undergeneral
anesthesia, the patient underwent laparotomy and surgical
exploration of the pancreas; a 10mm nodule was found
where indicated by digital angiography and was enucleated
from the pancreatic tail without local complications or
bleeding. Enucleation was performed with care to spare the
surrounding pancreatic tissue, using the CUSA EXcel (Tyco)
ultrasonic surgical aspiration system (Figures 1(d) and 1(e)).
2.4. Tissue Analysis. The sample was ﬁxed in formalin
and sections stained with hematoxylin and eosin and
Schiﬀ period acid reaction (to visualize capillary base-
ment membranes) using standard commercially available
kits. Immunohistochemistry was performed with antibod-
ies directed against CD34 (to stain capillaries), chromo-
granin and synaptophyin (neuroendocrine tumor markers),
insulin, and proinsulin (clone GS9A8, Developmental Stud-
ies Hybridoma Bank, University of Iowa). The nodule was
composed of a solid tumor with a pseudocapsule, made up
of conﬂuent growing areas of highly vascularized endocrine
pancreatic tissue. Neoplastic cells were monomorphic, with
abundant granular cytoplasm and central nuclei; they
were in close contact with capillary basement membranes
(reminiscent of an endocrine nature). Strong staining for
chromogranin and synaptophyin conﬁrmed the neuroen-
docrine origin of the tissue. Insulin staining was weak and
inhomogeneous among cells, while proinsulin staining was
stronger and more homogenous (Figure 2).
2.5. Followup. Four weeks after the removal of the nodule,
proinsulin (0.5pmol/L; 4.0pg/mL) and insulin (15pmol/L
(2.1mU/L)) concentrations were normal. At the last tele-
phone contact, 3 months after surgery, the patient had no
more complained hypoglycemic symptoms.
3. Discussion
The clinical history of this patient was highly suggestive of
an organic hypoglycemia. However, the low plasma insulin
concentrations, in relation to glucose levels, induced caution
in referring the patient to the surgeon and an extensive
imaging workup was performed. In fact, even with dedicated
imaging techniques, accessory spleens have been sometimes
confused with insulinomas and vice versa [3, 4]. The high
proinsulin concentrations could be indicative of the presence
of a proinsulinoma; importantly, the plasma proinsulin assay
used does not cross-react with intact human insulin or other
proinsulin fragments. It has been previously pointed out
that the use of highly speciﬁc plasma insulin immunoas-
says reduce the chances of identifying patients with high
proinsulin concentrations and possible proinsulinomas [5,
6]. However, proinsulin-only secreting tumors are very rare
(a few cases are described in the literature [6–9]) while
pancreatic endocrine tumors usually produce and secrete
both insulin and proinsulin [10, 11]. Anatomical diagnosis
was ﬁnally conﬁrmed with selective angiography, the most
invasive and accurate approach, providing information of
vascular density and origin. Remarkably, there was no
increase in proinsulin concentrations after calcium stimu-
lation, in agreement with the observation that proinsulin
is much less responsive to this test than insulin [12]. This4 Case Reports in Medicine
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Figure 2: Histopathological analysis of the surgical specimen. (a) Hematoxylin and eosin staining (low magniﬁcation) showing gross
appearance of the tissue and presence of a pseudocapsule with variable thickness. (b) Hematoxylin and eosin staining (200x) showing
monomorphic cells with abundant granular cytoplasm and central nuclei, in contact with capillary basement membranes, stained with
Period-Acid Schiﬀ (PAS) reaction (c, 200x). (d) Capillaries are stained with anti-CD34 (200x). The strong chromogranin (e) and
Synaptophysin (f) immunoreactivity indicates a neuroendocrine origin, while the few areas staining for cytokeratin-7 (g) are residual
exocrine tissue (100x). A visual comparison between insulin (h) and proinsulin (i) staining (200x) suggests a stronger proinsulin
immunoreactivity.
observation may underline that adenomas with proinsulin-
only or predominant proinsulin over insulin secretion are
less responsive to calcium stimulation, likely because of their
more immature nature compared with typical insulinomas.
A detailed pr-operative clinical and imaging characterization
is critical crucial to guide surgery. Octreotide scintigraphy
was not considered for its low negative predictive value in
the diagnosis of insulinomas, while labeled exendin-4 [13]
and 18F L-DOPA positron emission tomography were not
routinely available, and their value has yet to be conﬁrmed
in the diagnosis of insulinomas [14, 15].
In this case, an enucleative conservative approach lead to
a favorable prognosis, without exposing the patient to larger
pancreatic resection and risk of developing diabetes.
Histopathological analysis conﬁrmed the classic neu-
roendocrine nature of the adenoma, with blunted insulin
immunoreactivity and higher proinsulin content. Remark-
ably, the GS-9A8 antibody clone used for proinsulin
immunostaining does not cross-react with human insulin
or c-peptide, providing an unbiased picture of proinsulin
content. Finally, the resolving of symptoms and the drop
in proinsulin concentrations after the removal of the tumor
conﬁrmed the diagnosis of proinsulinoma.
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